abstract |
The present invention relates to the field of biology, and relates to single domain antibodies to the programmed killing ligand (PDL1) and protein derivatives thereof. In particular, the invention relates to the use of a programmed killing ligand 1 (PDL1) binding molecule and its use, preferably for the treatment and / or prevention or diagnosis of PDL1 related diseases such as tumors. |